Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated ...

Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...

Varshavski: I asked a bunch of different specialists what's the one medical breakthrough they're excited about in their ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Age differences are seen in the efficacy of treatments for type 2 diabetes, according to study results published in the Journal of the AMA.

ETH researchers have developed a new gene switch that can be activated using a commercially available nitroglycerine patch ...

NSYNC’s Lance Bass shares his journey with type 1.5 diabetes, also known as latent autoimmune diabetes in adults (LADA). The ...

A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...